At a glance
An experimental peptide designed to study senescent-cell survival.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The cited work concerns senescent-cell burden and tissue responses. These findings do not establish a clinical anti-aging regimen.[2][3][4]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of FOXO4-DRI.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 250 mcg | 7.5 units (0.075 mL) |
| Weeks 5–8 | 375 mcg | 11 units (0.11 mL) |
| Weeks 9–12 | 500 mcg | 15 units (0.15 mL) |
| Weeks 13–16 | 500 mcg | 15 units (0.15 mL) |
Frequency: Inject once daily subcutaneously[6]. This schedule uses the standard 3.0 mL dilution to maintain injection volumes under 0.2 mL for all doses. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Selectively clear senescent cells via disruption of FOXO4–p53 binding[1][2].
- Schedule: Daily subcutaneous injections for 8–16 weeks with gradual dose escalation.
- Dose Range: 250–500 mcg daily; starting low and titrating upward over time.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw[7].
Suggested daily titration approach.
- Start: 250 mcg daily for the first 4 weeks; increase gradually as tolerated.
- Mid-Phase: 375 mcg daily during Weeks 5–8.
- Target: 500 mcg daily by Weeks 9–16.
- Frequency: Once per day (subcutaneous)[6].
- Cycle Length: 8–16 weeks; longer cycles may use intermittent dosing schedules as tolerated[3].
- Timing: Any consistent time; rotate injection sites to minimize local irritation.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake)[7].
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; minimize moisture exposure[7].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 1 month when using bacteriostatic water[7].
- Allow vials to reach room temperature before opening to reduce condensation uptake.
- If long-term storage of reconstituted solution is needed, aliquot into single-use vials and freeze to minimize degradation[7].
Injection Technique
General subcutaneous guidance from clinical best-practice resources[8][9][10].
- Clean the vial stopper and skin with alcohol; allow to dry[8].
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue (use 90° for adequate fat layer, 45° if thin)[10][11].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[10].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy and local irritation[9].
- Release the pinch and withdraw the needle; apply gentle pressure with gauze if slight bleeding occurs.
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (FOXO4-DRI, 10 mg each):
- 8 weeks ≈ 3 vials
- 12 weeks ≈ 4 vials
- 16 weeks ≈ 5 vials
-
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 07
- 08
Public health resource
MedlinePlus — Subcutaneous (SQ) injections: technique, site selection, and safety (opens in a new tab)medlineplus.gov
Back to overview ↑ - 09
Source document
American Diabetes Association — Insulin injection site rotation and lipohypertrophy prevention (opens in a new tab)diabetesjournals.org
Back to overview ↑ - 10
Public health resource
CDC — Vaccine administration: subcutaneous route (angle, site; no aspiration) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 11
- 12
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 13
Research publication
PMC — Subcutaneous Drug Injection Review: pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑